BWXT Medical

What BWXT Medical does

BWXT Medical Ltd. is a radiopharmaceutical manufacturer and supplier serving the global nuclear medicine industry. It is a privately held subsidiary of BWX Technologies, Inc. (headquartered in Lynchburg, Virginia) and operates a CNSC-licensed nuclear medicine manufacturing facility in Kanata, Ontario, Canada. The company produces and distributes pharmaceutical-grade radioisotopes and radiochemical solutions used in diagnostic imaging and targeted cancer therapies, serving healthcare providers, pharmaceutical companies, and research institutions across more than 40 countries.

The company's commercial product portfolio includes Actinium-225 (an alpha-emitting therapeutic isotope), Germanium-68 Chloride Radiochemical Solution (a parent for Ga-68 PET generators), Indium-111 and Indium-111 Oxyquinoline Solution (for diagnostic imaging including infection detection), Iodine-123 and Sodium Iodide-123 Oral Solution (for thyroid imaging), and Strontium-82 (a parent for Rb-82 cardiac PET generators). An active development pipeline adds Lutetium-177 (therapeutic), Lead-203 (diagnostic), a Target Delivery System, and Technetium-99m Generators — the latter targeting the most widely used medical radioisotope globally. The company manufactures both finished products and active pharmaceutical ingredients used in end-patient diagnostic and therapeutic applications.

BWXT Medical generates revenue through direct commercial sales of radiopharmaceutical products and through related services (including regulatory compliance and manufacturing support) to enterprise buyers in the healthcare and pharmaceutical sectors. Pricing is not publicly disclosed. The go-to-market model is enterprise field sales, supported by participation in major industry events such as SNMMI, with regulated distribution requiring specialized radioactive material handling and cold-chain logistics. The company holds no public ticker, has no disclosed funding rounds, and operates within the consolidated structure of its NYSE-listed parent.

Name

BWXT Medical

Legal name

BWXT Medical Ltd.

Website

https://bwxtmedical.com

Company type

Private

Operating status

Operating

Short description

BWXT Medical Ltd. is a privately held subsidiary of BWX Technologies that manufactures pharmaceutical-grade radioisotopes and radiopharmaceutical products for diagnostic imaging and targeted cancer therapies, serving healthcare providers, pharmaceutical companies, and research institutions across 40+ countries from its CNSC-licensed facility in Kanata, Canada.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

Keywords

• Radiopharmaceutical manufacturing
• Nuclear medicine products
• Medical radioisotope supply
• Diagnostic imaging isotopes
• Cancer therapy radiopharmaceuticals

Headquarters

HQ city

Kanata

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. Radiopharmaceutical Products: Sale of nuclear medicine products including radioisotopes and radiochemical solutions to healthcare providers and pharmaceutical companies for diagnostic and therapeutic applications
2. Nuclear Medicine Services: Service offerings for the global nuclear medicine industry including regulatory compliance and manufacturing support

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BWXT Medical develops and manufactures pharmaceutical-grade radiopharmaceutical products, including medical radioisotopes (Actinium-225, Germanium-68, Indium-111, Iodine-123, Strontium-82) and radiochemical solutions, used in nuclear medicine diagnostic imaging and targeted cancer therapies. The company also provides nuclear medicine services such as regulatory compliance support and manufacturing services, and maintains a pipeline of therapeutic radioisotopes (Lutetium-177, Lead-203) and delivery systems for the global nuclear medicine industry.

Product overview

BWXT Medical is a leading product developer and service provider for the global nuclear medicine industry. The company offers a portfolio of radiopharmaceutical products including Actinium-225 (therapeutic), Germanium-68 Chloride Radiochemical Solution, Indium-111, Indium-111 Oxyquinoline Solution, Iodine-123, Sodium Iodide-123 Oral Solution, and Strontium-82. Their product pipeline includes Lead-203, Lutetium-177, a Target Delivery System, and Technetium-99m Generators. The company manufactures both finished products and active pharmaceutical ingredients used in the production of end patient detection and treatments, enabling clinical trials and life-saving treatments in over 40 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Actinium-225 Alpha-emitting radioisotope product used in nuclear medicine for therapeutic applications, including targeted cancer therapies. Sold to healthcare providers and pharmaceutical companies for drug development.
• Germanium-68 Chloride Radiochemical Solution Radiochemical solution used as a positron emission tomography (PET) radionuclide generator parent, providing Gallium-68 for diagnostic imaging in nuclear medicine.
• Indium-111 Gamma-emitting radioisotope used in nuclear medicine imaging for diagnostic applications, including infection detection and tumor imaging.
• Indium-111 Oxyquinoline Solution Radiopharmaceutical product used for labeling white blood cells in nuclear medicine imaging for infection detection.
• Iodine-123 Radioisotope used for thyroid imaging and other diagnostic nuclear medicine procedures.
• Sodium Iodide-123 Oral Solution Oral solution formulation of Sodium Iodide-123 for thyroid diagnostic imaging.
• Strontium-82 Parent radioisotope used in generators to produce Rubidium-82 for cardiac PET imaging.
• Nuclear Medicine Services Service offerings for the global nuclear medicine industry, including regulatory compliance support and manufacturing services. Targeted at pharmaceutical companies and clinical research institutions.

Quantifiable outcome

• Patient treatments enabled in over 40 countries worldwide
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• Canadian Nuclear Safety Commission (CNSC)coreOthersRegulatory relationship for compliance and oversight of the Kanata facility. BWXT Medical submits Annual Compliance Reports to CNSC as part of regulatory requirements for operating a nuclear medicine manufacturing facility.

Scale indicators3 records

Recent moves5 records

Expansion highlights8 records

Direct peers

• NorthStar Medical Radioisotopes: U.S.-based commercial producer of Mo-99/Tc-99m and other medical radioisotopes using non-uranium production methods. Directly comparable in radioisotope manufacturing, regulatory pathway, and customer base (nuclear medicine departments and radiopharmacies).
• IBA Molecular: Specialty radiopharmaceutical producer offering PET and SPECT tracers plus isotope production technology. Direct peer in commercial radioisotope supply to hospitals and pharmaceutical partners worldwide.
• Lantheus Holdings: Specialty radiopharmaceutical company focused on diagnostic imaging agents and increasingly therapeutic radioligands (e.g., PNT2002). Comparable in commercial-stage nuclear medicine products and pharmaceutical-grade manufacturing, though larger and publicly traded.
• Curium Pharma: One of the largest commercial manufacturers of radiopharmaceuticals and nuclear medicine products globally, offering SPECT and PET isotopes and finished doses. Directly comparable to BWXT Medical across product categories, customer base, and regulatory positioning.
• Eckert & Ziegler: European-headquartered manufacturer of radiopharmaceuticals, radioisotopes, and radiation therapy sources. Comparable product portfolio across diagnostic isotopes, therapy sources, and contract manufacturing services.

Emerging players

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents (e.g., Illuccix for PSMA imaging). Comparable in targeting pharmaceutical-grade radiopharma supply for oncology and imaging customers.

Broad incumbents

• Cardinal Health (Nuclear & Precision Health Solutions): Operates the largest U.S. radiopharmacy distribution network supplying finished unit doses to hospitals. Comparable in distributing/manufacturing radiopharmaceuticals for the same healthcare-provider segment, though primarily as a downstream pharmacy rather than primary isotope producer.
• GE HealthCare (PETNET Solutions): Operates one of the largest PET tracer and SPECT isotope distribution networks via PETNET. Comparable because it supplies diagnostic nuclear medicine products to the same healthcare-provider customer base, though as part of a much broader medical-imaging portfolio.
• PETNET Solutions (Siemens Healthineers): Operates a global network of cyclotron-equipped radiopharmacy sites producing F-18, C-11 and other PET tracers. Comparable in supplying nuclear medicine diagnostic agents to hospitals and research institutions.
• Bayer (Radiology / Curium JV stake): Sells Xofigo (Ra-223) and other radiopharmaceuticals through its radiology business and has historical radiopharma joint ventures. Comparable therapeutic radiopharma franchise competing for the same oncology customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/BWXT
• YouTubeyoutube.com/channel/UCSgCJ1E5p9alNfmbF_bGFWg
• Facebookfacebook.com/bwxtcanada
• LinkedInlinkedin.com/company/bwxt-medical-ltd
• Instagraminstagram.com/bwxtechnologies

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BWXT Medical